Alnylam Competitors and Similar CompaniesClear all

Reata Pharmaceuticals's competitors and similar companies include Celyad, Sorrento Therapeutics, Regulus Therapeutics, Sarepta Therapeutics and Ionis Pharmaceuticals.
Reata Pharmaceuticals
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.
Celyad
Celyad
Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
Sorrento Therapeutics
Sorrento Therapeutics
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
Regulus Therapeutics
Regulus Therapeutics
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
Sarepta Therapeutics
Sarepta Therapeutics
Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases.
Ionis Pharmaceuticals
Ionis Pharmaceuticals
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
Founding Date
Founding Date
2002
Founding Date
2007
Founding Date
2006
Founding Date
2007
Founding Date
1980
Founding Date
1989
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Plano, US HQ
Irving, US
Plano, US
Locations
Mont-Saint-Guibert, BE HQ
New York, US
Locations
San Diego, US HQ
San Diego, US
Locations
San Diego, US HQ
Locations
Cambridge, US HQ
Dublin, IE
Zug, CH
Providence, US
Locations
Carlsbad, US HQ
Employees
Employees
3217% decrease
Employees
17
Employees
31019% decrease
Employees
2462% decrease
Employees
1,31413% increase
Employees
92716% increase
Valuation ($)
Valuation ($)
6.6 b
Valuation ($)
12.1 m
Valuation ($)
1.5 m
Valuation ($)
105.4 m
Valuation ($)
12.4 b
Valuation ($)
6.3 b

Financial

Revenue (est.)
Revenue (est.)
$2.2m (FY, 2022)
Revenue (est.)
€102k (FY, 2023)
Revenue (est.)
$62.8m (FY, 2022)
Revenue (est.)
N/A
Revenue (est.)
$1.2b (FY, 2023)
Revenue (est.)
$787.6m (FY, 2023)
Cost of goods
Cost of goods
N/A
Cost of goods
€69k (FY, 2023)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$150.3m (FY, 2023)
Cost of goods
$9.1m (FY, 2023)
Gross profit
Gross profit
N/A
Gross profit
€1.4m (FY, 2023)
Gross profit
N/A
Gross profit
N/A
Gross profit
$1.1b (FY, 2023)
Gross profit
$778.5m (FY, 2023)
Net income
Net income
($311.9m) (FY, 2022)
Net income
(€8.4m) (FY, 2023)
Net income
($577.8m) (FY, 2022)
Net income
($30m) (FY, 2023)
Net income
($536m) (FY, 2023)
Net income
($366.3m) (FY, 2023)

Operating

Patents Issued
Patents Issued
240 (FY, 2016)
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
300 (FY, 2016)
Patents Issued
N/A
Patents Issued
N/A
Phase I Trials Products
Phase I Trials Products
2 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2023)
Phase II Trials Products
Phase II Trials Products
4 (FY, 2016)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
13 (FY, 2023)
Phase III Trials Products
Phase III Trials Products
1 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
9 (FY, 2023)

Funding

Total funding raised
Total funding raised
$ 468.9m
Total funding raised
N/A
Total funding raised
$ 42.6m
Total funding raised
$ 10m
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profile

View Company Profiles

Celyad
HQ
Mont-Saint-Guibert, BE
Employees
17

Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.

View company
Sorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease

Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.

View company
Regulus Therapeutics
HQ
San Diego, US
Employees
24

Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.

View company
Sarepta Therapeutics
HQ
Cambridge, US
Employees
1,314↑ 13% increase

Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases.

View company